Acadia Pharmaceuticals | ACAD - Actif À Court Terme





Actif À Court Terme Changement Date
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Cara Therapeutics USD 31.54M 6.9M 2025-12
Corcept Therapeutics USD 426.03M 59.43M 2026-03
Cytokinetics USD 839.46M 77.51M 2026-03
Eisai JPY 761.64B 79.24B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Incyte USD 5.48B 460.36M 2026-03
J&J USD 59.17B 3.55B 2026-03
Moderna USD 5.77B 774M 2026-03
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Pfizer USD 42.82B 76M 2026-03
Prothena USD 339.2M 24.01M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03